CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SPRED3 (ImmuneEditome ID:399473)

1. Gene summary of enriched editing regions for SPRED3

check button Gene summary
Gene informationGene symbol

SPRED3

Gene ID

399473

GeneSynonymsEve-3|spred-3
GeneCytomap

19q13.2

GeneTypeprotein-coding
GeneDescriptionsprouty-related, EVH1 domain-containing protein 3
GeneModificationdate20230329
UniprotIDQ2MJR0;K7EKP4;K7EPT9;K7EPU5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:38397380-38398546:+ENST00000338502.7ENSG00000188766.11SPRED3UTR3(TATT)n,FLAM_C,AluSx3chr19:38397380-38398546:+.alignment


Top

2. Tumor-specific enriched editing regions for SPRED3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for SPRED3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:38397380-38398546:+GBMEERENSG00000197536,C5orf560.46331.5512e-051.3747e-130.5730imageNDGCR8;EIF4A3;FBL;FUS;HNRNPA1;HNRNPK;HNRNPM;NONO;RBFOX2;SRSF1;TRA2A;U2AF2NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:38397380-38398546:+GBMEERENSG00000150540,HNMT0.43757.7279e-053.6439e-080.4449imageNDDX3X;DGCR8;EIF4A3;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPK;HNRNPM;PRPF8;RBFOX2;SRSF1;SRSF9;TRA2A;U2AF2HNMTMacrophages_M0GSVA_HALLMARK_APICAL_JUNCTION
chr19:38397380-38398546:+GBMEERENSG00000137959,IFI44L0.42641.4303e-043.1929e-090.4744imageNDGCR8;EIF4A3;FBL;FUS;SRSF1;U2AF2IFI44LMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:38397380-38398546:+GBMEERENSG00000135899,SP1100.42051.7767e-046.8555e-140.5788imageNCNBP;DDX3X;DGCR8;EIF4A3;FAM120A;FBL;FUS;HNRNPA1;HNRNPK;LARP4B;PRPF8;RBFOX2;SRSF1;U2AF2SP110Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:38397380-38398546:+GBMEERENSG00000115267,IFIH10.40873.0936e-049.6733e-110.5124imageNCNBP;DGCR8;EIF4A3;FBL;FUS;FXR1;HNRNPA1;PRPF8;RBM10;SRSF1;SRSF9;U2AF2IFIH1Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:38397380-38398546:+GBMEERENSG00000119922,IFIT20.40304.1380e-044.4697e-100.4964imageNEIF4A3;FBL;FUS;SRSF1;SRSF9;U2AF2IFIT2Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:38397380-38398546:+GBMEERENSG00000164342,TLR30.39914.8279e-041.0549e-100.5115imageNEIF4A3;FBL;HNRNPA1;SRSF1TLR3Macrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:38397380-38398546:+GBMEERENSG00000163644,PPM1K0.38777.0908e-049.1962e-110.5129imageNCNBP;DDX3X;DGCR8;EIF4A3;FAM120A;FBL;FUS;HNRNPA1;HNRNPK;HNRNPM;LARP4B;NONO;PRPF8;RANGAP1;RBFOX2;RBM10;SRSF1;SRSF9;U2AF2NAMacrophages_M0GSVA_HALLMARK_ANGIOGENESIS
chr19:38397380-38398546:+GBMEERENSG00000155324,GRAMD30.38837.1286e-044.8307e-070.4102imageNDGCR8;EIF4A3;FAM120A;FBL;FUS;HNRNPA1;HNRNPK;HNRNPM;PRPF8;RBFOX2;RBM10;SRSF1;SRSF9;TRA2A;U2AF2NAMast_cells_restingGSVA_HALLMARK_BILE_ACID_METABOLISM
chr19:38397380-38398546:+GBMEERENSG00000080546,SESN10.38697.5388e-047.0588e-110.5156imageNCNBP;DGCR8;EIF4A3;FAM120A;FBL;FUS;FXR1;HNRNPA1;HNRNPK;HNRNPM;LARP4B;NONO;PRPF8;RANGAP1;RBFOX2;RBM10;SRSF1;SRSF9;TRA2A;U2AF2NAMacrophages_M0GSVA_HALLMARK_MYC_TARGETS_V2

More results



Top

4. Enriched editing regions and immune related splicing for SPRED3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000188766.11,SPRED3
PCPGEAGA5ENSG00000019144.12chr11118635392:118635550:118635023:118635163:118635023:1186350510.36731.0778e-035.9457e-100.5148imageNADAR;BCCIP;CSTF2T;DDX42;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAMast_cells_activatedGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000188766.11,SPRED3
PCPGEAGMEXENSG00000106400.7chr7101218180:101218217:101218318:101218435:101221245:101221796:101222603:101222774-0.34401.1406e-028.3289e-07-0.4092imageNADAR;BCCIP;CSTF2T;DDX42;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAGSVA_HALLMARK_COAGULATION
ENSG00000188766.11,SPRED3
PCPGEAGMEXENSG00000106400.7chr7101218180:101218217:101218318:101218435:101221408:101221796:101222603:101222774-0.33541.5906e-021.1550e-06-0.4043imageNADAR;BCCIP;CSTF2T;DDX42;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAGSVA_HALLMARK_COAGULATION
ENSG00000188766.11,SPRED3
PCPGEAGESENSG00000182179.6chr349812447:49812543:49812647:49812738:49813061:49813168-0.26032.1746e-024.2749e-09-0.5081imageNBCCIP;CSTF2T;DDX42;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;LSM11;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2;XRN2;ZNF184NAPlasma_cellsGSVA_HALLMARK_MYC_TARGETS_V1
ENSG00000188766.11,SPRED3
PCPGEAGESENSG00000148341.13chr9129010669:129010693:129012138:129012298:129014410:1290144580.30235.7288e-031.1272e-070.4435imageNADAR;BCCIP;CSTF2T;DDX42;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NANK_cells_restingGSVA_HALLMARK_GLYCOLYSIS
ENSG00000188766.11,SPRED3
PCPGEAGMEXENSG00000106400.7chr7101218180:101218217:101218318:101218435:101221616:101221796:101222603:101222774-0.34998.9380e-036.3141e-07-0.4132imageNADAR;BCCIP;CSTF2T;DDX42;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000188766.11,SPRED3
PCPGEAGMEXENSG00000106400.7chr7101218180:101218217:101218318:101218435:101220306:101221796:101222603:101222774-0.33331.7914e-021.0730e-06-0.4054imageNADAR;BCCIP;CSTF2T;DDX42;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAGSVA_HALLMARK_HEDGEHOG_SIGNALING
ENSG00000188766.11,SPRED3
PCPGEAGMEXENSG00000106400.7chr7101218180:101218217:101218318:101218435:101221644:101221796:101222603:101222774-0.33991.3436e-029.6587e-07-0.4070imageNADAR;BCCIP;CSTF2T;DDX42;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAGSVA_HALLMARK_KRAS_SIGNALING_DN
ENSG00000188766.11,SPRED3
PCPGEAGIRENSG00000135439.7chr1257726973:57727771:57727936:577280850.41656.5181e-045.9610e-070.4045imageNADAR;CSTF2T;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA2B1;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;NOP56;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;SLTM;SRSF1;SRSF3;TAF15;U2AF2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_HEDGEHOG_SIGNALING
ENSG00000188766.11,SPRED3
PCPGEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.48351.2290e-055.3993e-10-0.4912imageNADAR;BCCIP;CSTF2T;DDX42;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LSM11;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184PRKCSHT_cells_CD4_memory_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS

More results



Top

5. Enriched editing regions and immune infiltration for SPRED3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000188766.11,SPRED3BLCAEAGMast_cells_activated2.9031e-03-0.5923image
chr19:38397380-38398546:+BRCAEERT_cells_regulatory_(Tregs)2.2590e-040.2340image
ENSG00000188766.11,SPRED3BRCAEAGT_cells_regulatory_(Tregs)1.2809e-020.1494image
chr19:38397380-38398546:+ESCAEEREosinophils1.0782e-020.3143image
ENSG00000188766.11,SPRED3ESCAEAGEosinophils3.7594e-030.3468image
chr19:38397380-38398546:+GBMEERMacrophages_M01.2155e-04-0.3191image
ENSG00000188766.11,SPRED3GBMEAGMacrophages_M02.1436e-04-0.3069image
chr19:38397380-38398546:+KIRCEERMonocytes1.9154e-020.3998image
ENSG00000188766.11,SPRED3KIRCEAGMonocytes2.2388e-030.4538image
chr19:38397380-38398546:+LGGEERMacrophages_M01.4327e-04-0.2492image
ENSG00000188766.11,SPRED3LGGEAGMonocytes1.0374e-050.2738image
chr19:38397380-38398546:+LUADEERMacrophages_M11.2079e-02-0.2904image
ENSG00000188766.11,SPRED3LUADEAGT_cells_regulatory_(Tregs)4.2330e-020.2195image
chr19:38397380-38398546:+LUSCEERDendritic_cells_resting9.0206e-030.3167image
ENSG00000188766.11,SPRED3LUSCEAGDendritic_cells_resting8.0403e-030.3019image
chr19:38397380-38398546:+OVEERT_cells_follicular_helper1.3790e-020.2493image
ENSG00000188766.11,SPRED3OVEAGT_cells_follicular_helper2.2686e-020.2191image
ENSG00000188766.11,SPRED3PAADEAGNeutrophils1.0331e-020.3113image
chr19:38397380-38398546:+PCPGEERT_cells_regulatory_(Tregs)1.2608e-020.2244image
ENSG00000188766.11,SPRED3PCPGEAGPlasma_cells1.8731e-050.3508image
ENSG00000188766.11,SPRED3SARCEAGMast_cells_resting4.4052e-020.3702image
chr19:38397380-38398546:+SKCMEERT_cells_follicular_helper3.8117e-020.2120image
ENSG00000188766.11,SPRED3SKCMEAGT_cells_follicular_helper2.7418e-020.2195image
chr19:38397380-38398546:+STADEERMonocytes4.1078e-030.2874image
ENSG00000188766.11,SPRED3STADEAGMonocytes2.7359e-030.2781image
chr19:38397380-38398546:+THCAEERMacrophages_M22.4497e-02-0.2249image
ENSG00000188766.11,SPRED3THCAEAGMacrophages_M27.4154e-03-0.2347image
ENSG00000188766.11,SPRED3UCECEAGPlasma_cells2.2487e-040.7347image


Top

6. Enriched editing regions and immune gene sets for SPRED3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000188766.11,SPRED3LGGEAG3.8519e-02-0.13045.9164e-03-0.17295.1923e-03-0.17562.3295e-02-0.1429image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:38397380-38398546:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.1651e-070.3172image
ENSG00000188766.11,SPRED3BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.9381e-050.2444image
chr19:38397380-38398546:+ESCAGSVA_HALLMARK_COMPLEMENTEER5.7330e-03-0.3390image
ENSG00000188766.11,SPRED3ESCAGSVA_HALLMARK_COMPLEMENTEAG6.1386e-03-0.3291image
chr19:38397380-38398546:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.6424e-040.2971image
ENSG00000188766.11,SPRED3GBMGSVA_HALLMARK_ANGIOGENESISEAG1.1156e-04-0.3197image
ENSG00000188766.11,SPRED3HNSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.2588e-02-0.2913image
chr19:38397380-38398546:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER3.7390e-03-0.1913image
ENSG00000188766.11,SPRED3LGGGSVA_HALLMARK_ANGIOGENESISEAG1.8269e-04-0.2336image
chr19:38397380-38398546:+LUADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER9.6447e-03-0.2991image
ENSG00000188766.11,SPRED3LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG7.2459e-03-0.2876image
chr19:38397380-38398546:+LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.0991e-02-0.2638image
ENSG00000188766.11,SPRED3LUSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.4723e-02-0.2310image
chr19:38397380-38398546:+OVGSVA_HALLMARK_MITOTIC_SPINDLEEER7.4159e-03-0.2703image
ENSG00000188766.11,SPRED3OVGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG3.3805e-020.2044image
ENSG00000188766.11,SPRED3PAADGSVA_HALLMARK_HYPOXIAEAG9.1036e-030.3164image
ENSG00000188766.11,SPRED3PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.2789e-04-0.2972image
chr19:38397380-38398546:+SKCMGSVA_HALLMARK_ANGIOGENESISEER2.1217e-02-0.2349image
ENSG00000188766.11,SPRED3SKCMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.1022e-020.2520image
chr19:38397380-38398546:+STADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.1191e-020.2066image
chr19:38397380-38398546:+THCAGSVA_HALLMARK_UV_RESPONSE_DNEER6.2496e-03-0.2717image
ENSG00000188766.11,SPRED3THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.2660e-03-0.2500image
ENSG00000188766.11,SPRED3UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.9666e-02-0.4633image


Top

7. Enriched editing regions and drugs for SPRED3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000188766.11,SPRED3BLCADoxorubicinEAG1.7655e-020.4899image
chr19:38397380-38398546:+BRCAAZD6244EER9.3679e-03-0.1660image
ENSG00000188766.11,SPRED3BRCAElesclomolEAG3.8390e-03-0.1732image
chr19:38397380-38398546:+ESCACGP.082996EER7.8133e-03-0.3272image
ENSG00000188766.11,SPRED3ESCACGP.082996EAG1.4969e-02-0.2940image
chr19:38397380-38398546:+GBMATRAEER1.8148e-07-0.4238image
ENSG00000188766.11,SPRED3GBMATRAEAG8.6282e-08-0.4323image
ENSG00000188766.11,SPRED3HNSCJNK.9LEAG3.9091e-02-0.2816image
chr19:38397380-38398546:+KIRCLapatinibEER3.0677e-02-0.3712image
chr19:38397380-38398546:+LGGBX.795EER1.9138e-060.3093image
ENSG00000188766.11,SPRED3LGGBX.795EAG1.7005e-060.2962image
chr19:38397380-38398546:+LUADAICAREER2.9754e-040.4089image
ENSG00000188766.11,SPRED3LUADCytarabineEAG7.1852e-030.2879image
chr19:38397380-38398546:+LUSCMetforminEER1.6931e-02-0.2909image
ENSG00000188766.11,SPRED3LUSCMetforminEAG9.6876e-03-0.2950image
chr19:38397380-38398546:+OVBexaroteneEER6.9655e-040.3385image
ENSG00000188766.11,SPRED3OVBI.2536EAG1.8452e-020.2264image
ENSG00000188766.11,SPRED3PAADCyclopamineEAG1.3965e-02-0.2990image
chr19:38397380-38398546:+PCPGLapatinibEER9.4722e-03-0.2331image
ENSG00000188766.11,SPRED3PCPGJNJ.26854165EAG6.2164e-04-0.2837image
ENSG00000188766.11,SPRED3SARCEmbelinEAG7.9101e-030.4755image
chr19:38397380-38398546:+SKCMJNK.9LEER7.1063e-03-0.2731image
ENSG00000188766.11,SPRED3SKCMBMS.708163EAG1.1961e-020.2492image
chr19:38397380-38398546:+STADCGP.60474EER3.9928e-040.3507image
ENSG00000188766.11,SPRED3STADCGP.60474EAG4.1625e-050.3739image
chr19:38397380-38398546:+THCAEmbelinEER1.0783e-050.4244image
ENSG00000188766.11,SPRED3THCAGefitinibEAG1.7423e-03-0.2731image
ENSG00000188766.11,SPRED3UCECCHIR.99021EAG1.8512e-020.5209image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType